Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Clinical Cardiology|June 18, 2010
Natriuretic and neurohormonal responses to nesiritide, furosemide, and combined nesiritide and furosemide in patients with stable systolic dysfunctionDomenic Sica, Ron M Oren, Mildred D Gottwald, et al.Journal of the American College of Cardiology|April 25, 2006
Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patientsWilliam T Abraham, Alireza A Shamshirsaz, Kim McFann, et al.The American Journal of Cardiology|September 3, 2004
Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial)Clyde W Yancy, Mitchell T Saltzberg, Robert L Berkowitz, et al.American Heart Journal|December 15, 2010
Prospective evaluation of the association between cardiac troponin T and markers of disturbed erythropoiesis in patients with heart failureKirkwood F Adams, Mandeep R Mehra, Ron M Oren, et al.Journal of Cardiac Failure|March 9, 2010
Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failureLarry A Allen, G Michael Felker, Mandeep R Mehra, et al.American Heart Journal|December 5, 2009
Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failureKirkwood F Adams, Ileana L Piña, Jalal K Ghali, et al.American Heart Journal|April 21, 2009
Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) RegistryKirkwood F Adams, James H Patterson, John H Patterson, et al.American Heart Journal|May 4, 2010
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) programChristopher M O'Connor, Alan B Miller, John E A Blair, et al.Circulation|November 9, 2005
Continuous aortic flow augmentation: a pilot study of hemodynamic and renal responses to a novel percutaneous intervention in decompensated heart failureMarvin A Konstam, Barbara Czerska, Michael Böhm, et al.Pageof 2